Inclusion Criteria:

- adult patients, >=18 years of age;

- locally advanced metastatic or recurrent non-squamous non-small cell lung cancer
(NSCLC);

- >=1 measurable tumor lesion;

- ECOG performance status 0-1.

Exclusion Criteria:

- prior chemotherapy or treatment with another systemic anti-cancer agent;

- evidence of CNS metastases;

- history of grade 2 or higher hemoptysis;

- evidence of tumor invading or abutting major blood vessels;

- malignancies other than NSCLC within 5 years prior to randomization, other than
adequately treated cancer in situ of cervix, basal or squamous cell skin cancer,
localized prostate cancer or DCIS;

- clinically significant cardiovascular disease;

- current or recent use of aspirin (>325mg/day) or full dose anticoagulants or
thrombolytic agents for therapeutic purposes.